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Abstract 
 
Background: Anemia is a major cardiovascular risk 
factor in
 
renal disease. It might be appropriate to 
extrapolate this association
 
of anemia with cardiovascular 
disease to renal transplant recipients
 
who continue to 
have a significant cardiovascular risk. 
The aim of our study was to elucidate the prevalence and 
risk factors of anemia after kidney transplantation.
 
 
Methods:  We studied 118 stable adult kidney transplant 
recipients [age at transplant ranged between 22 and
 
58, 
42 ± 12], 74 (62.7%) were males and
 
44 were females 
(37.3%) who received
 
allograft between December 1998 
and October 2008 and had at
 
least 1 year of post-
transplant follow up data at Sugar Medical Center, 
Theodor Bilharz Research Institute (TBRI), and Health 
Insurance Organization Cairo.
 
Hemoglobin (Hb) level at 
6 months, and 1 year after renal transplantation
 
was 
recorded, the eGFR was calculated using the MDRD 
formula. Risk factors for anemia were evaluated using
 
univariate and multivariate regression analysis.
 
 
Results: Anemia (Hb <12 g/dl in females and
 
<13 g/dl in 
males) was common (28.8% at 6 months, 31.4% at
 
1 
year).
 
Significant anemia (Hb <11 g/dl in females and
 
<12 g/dl in males) was also common (15.3% at 6 months, 
16.8% at
 
1 year). Severe anemia (Hb <10 g/dl in both 
genders)
 
at 6 months post-transplant was less common 
affecting 4
 
out of 118 (3.4%) patients. At 1 year, 8
 
out of 
118 (6.8%) had ‗severe‘ anemia. Univariate and 
multivariate analysis showed
 
that a higher serum 
creatinine level and lower eGFR were significant
 
risk 
factors at 6 months and 1 year post transplant.
 
At 1 year, 
in addition to higher creatinine level and lower eGFR, 
female
 
gender and immunosuppressive drugs 
(azathioprine and sirolimus) also were significant risk 
factors. 
 
------------------                                                      
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Conclusions: Anemia is common during the first year 
after kidney
 
transplantation. High serum creatinine, low 
eGFR, female gender and immunosuppressive drugs 
[azathioprine, sirolimus] are independent risk factors for 
post-transplant
 
anemia. 
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Introduction 
  
Anemia in chronic kidney disease (CKD) is strongly 
associated with significant cardiovascular
 
morbidity [1], 
hospitalization [2] and mortality [3]. The development of 
erythropoiesis-stimulating
 
agents (ESAs) has made 
anemia a central part of the management
 
of patients with 
CKD stages III-V [4-6]. Following
 
successful renal 
transplantation, some correction of anemia
 
occurs via 
endogenous production of ESA from the engrafted 
kidney
 
but a significant proportion, about one-third of the 
subjects,
 
remain anemic [7-9]. Post-transplantation 
anemia (PTA)
 
is important as the commonest cause of 
graft loss is death with
 
a functioning graft, mostly due to 
an excess of cardiovascular
 
disease, and anemia is a well-
recognized and potent cardiovascular
 
risk factor.
 
Hence, 
it would be advisable to prevent
 
and treat anemia in 
kidney transplant recipients.
 
 
Both ‗early‘ and ‗late‘ PTA has been identified in this 
context and the distinction is important
 
in identifying 
etiological causes. ‗Early‘ PTA refers to anemia 
persisting, or arising relatively soon after
 
engraftment. 
Relevant potential etiological factors include
 
iron 
deficiency, infectious agents, donor age, prophylactic
 
and 
immunosuppressive therapy. ‗Late‘ PTA is associated 
with the decline in renal function observed in the context 
of
 
chronic allograft nephropathy or recurrent renal 
pathology [7,10].
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Aim of the study 
 
The aim of our study was to elucidate the prevalence and
 
risk factors for anemia during the first year after kidney
 
transplantation.  
 
Material and methods 
 
We studied 118 stable adult kidney transplant recipients 
who received
 
allograft between December 1998 and 
October 2008 and had at
 
least 1 year of post-transplant 
follow up data at Sugar Medical Center, Theodor Bilharz 
Research Institute (TBRI) and Health Insurance 
Organization Cairo, Egypt. The recorded data base 
including: etiology of end stage renal disease, pre-
transplant hemoglobin (Hb) level, age of the patients at 
time of transplant, Hb levels at 6 months and 1 year post 
transplant, serum creatinine and eGFR using MDRD 
formula at 6 months and 1 year post transplant, iron 
profiles (serum ferritin and transferin saturation), and 
immunosuppressive drugs and other medications. 
Definition of anemia: We adopted three different 
definitions for anemia. One is the
 
WHO criteria (Hb level 
<12 g/dl in females, and <13 g/dl
 
in males). We also 
arbitrarily defined ‗significant‘ anemia as Hb level 
<11g/dl in females and <12 g/dl in
 males and ‗severe‘ 
anemia as Hb level <10 g/dl
 
in both genders.
 
 
Methods: We recorded the Hb levels before 
transplantation, at 6 months
,
 and at 1 year after 
transplantation. The eGFR was calculated using the 
MDRD formula. We performed univariate and
 
multivariate analysis to find the risk factors for anemia.
 
The various variables, which are typically recognized as 
risk
 
factors for anemia were chosen for the univariate 
analysis.
 
These were creatinine level and eGFR (at 6 
months and 1 year after transplantation),
 
pre-transplant 
Hb level, female gender,
 
delayed graft function, acute 
rejection, use of ACEI or ARB, SLE as the underlying
 
disease. We compared the Hb of patients who
 
used AZA 
vs. MMF and cyclosporine vs sirolimus because most of 
the patients were on either
 
of these medications.
 
 
Statistical analysis: Data were expressed as mean ± SD 
unless indicated otherwise.
 
Partial correlation analysis
 
was done to determine the independent correlation of the 
different
 
factors affecting anemia/Hb levels after 
accounting for the
 
different confounding factors. The 
continuous variables at different
 
time points and in 
different groups of patients were compared
 
using the 
Student's t-test and a
 
P value of <0.05 was considered 
significant. Risk factors for anemia were evaluated using
 
univariate and multivariate regression analysis.
 
We used 
SPSS® software version 10.0 (SPSS Inc., Chicago,
 
IL, 
USA). 
 
Results 
 
Patient’s demographics: Among 118 patients [age at 
transplant ranged between 22 and
 
58, 42±12 
(mean±SD)], 74 (62.7%) were males and
 
44 were 
females (37.3%). Thirty-nine (33.1%), 38 (32.2%), 22 
(18.6%) and 8(6.8%) patients, respectively,
 
had diabetes 
mellitus (DM),  hypertension (HTN), glomerulonephritis 
(GN) and
  
systemic lupus erythematosus (SLE)  as the 
cause of end-stage renal disease (ESRD). All 118 
patients were
 
living donor transplant recipients [16 living 
related and 102 living unrelated donors]. Twenty-one 
(17.8%) patients had been on angiotensin
 
converting 
enzyme inhibitors (ACEI) or angiotensin receptor
 
blockers (ARB) for 1 year after transplantation. Ten 
patients
 
experienced delayed graft function and 20 
patients experienced acute rejection. Only 6 out of 118 
patients (5.1%) were
 
on EPO and 14 (11.9%) were on 
oral iron supplementation. 
 
Table 1.  Patients characteristics. 
 
 
Total number of patients 
 
118 
  
Age at transplant(years) 
 
22-58 (42±12 ; mean±SD)   
Gender Male 
Female 
74 
34 
62.7% 
37.3% 
Aetiology of ESRD DM 
HTN 
GN 
SLE 
Others 
39 
38 
22 
8 
11 
33.1% 
32.2% 
18.6% 
6.8% 
9.3% 
Type of transplant Related living donars 
Unrelated living donars 
16 
102 
13.6% 
86.4% 
Number of patients who had Acute rejection 
Delayed graft function 
20 
10 
16.9% 
8.5% 
Use of medications ACEI or ARBS 
MMF 
Azathioprine 
Cyclosporine 
Tacrolimus(prograf) 
Sirolimus(rapamycin) 
Corticosteroids 
Erythropiotin 
Iron supplement 
 
21 
54 
64 
76 
12 
30 
118 
6 
14 
17.8% 
45.8% 
54.2% 
64.4% 
10.2% 
25.4% 
100% 
5.1% 
11.9% 
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Immunosuppressive regimens were as follows; steroid 
(methylprednisolone
 
or prednisolone) was given to all the 
patients. Steroid
 
was tapered down to a maintenance dose 
of 10 mg/day, by 6 months post-transplant unless they 
were
 
treated for rejection. Eighty eight patients received 
calcineurin inhibitors
 
(76 patients on cyclosporine and 12 
patients on tacrolimus) and 30 patients received a 
sirolimus-based regimen. Target level of cyclosporine 
was 200–250 ng/ml during the first 3 months and 150–
200 ng/ml thereafter;
 
that of tacrolimus was 10–15 ng/ml 
during the first 3
 
months and 5–10 ng/ml thereafter and 
that of sirolimus was 5-15 ng/ml during the first 3
 
months and 5–10 ng/ml thereafter. Sixsty-four patients 
(54.2%)
 
were on an azathioprine (AZA)-based 
immunosuppressive regimen
 
and 54 (45.8%) were on a 
mycophenolate mofetil (MMF)-based
 
immuno-
suppressive regimen.
 
 
Iron profile was checked in 34 patients who had
 
anemia 
by WHO definition during the first  post-transplant year
 
and 14 out of those 34 anemic  patients had ferritin levels 
<100
 
mg/dl or transferrin saturation <20%. All patients 
of these iron deficient patients had iron supplementation.
 
Only six out of 34 patients were treated with EPO and all
 
of these patients had Hb <11 g/dl.
 
 
Prevalence of anemia (tables 2, 3 and figure 1): 
Pre-transplant Hb level was 10.8±0.3 g/dl Hb level 
increased to 12.8±1.3 g/dl
  
 at 6 months
 
and 12.6±1.4 g/dl 
at 1 year. The differences in Hb levels at both 6
 
months , 
1 year with pre-transplant levels were significant
 
(P<0.0001) but there was no significant difference in Hb 
level
 
between 6 months and 1 year (P<0.2566).  
 
Table 2. Hb levels in the pre-transplant, 6-month, and 1-year period 
after kidney transplantation. 
 
 
Hemoglobin 
levels 
 
 
Total (n.118) 
 
Male (n.74) 
 
Female (n.44) 
 
Pre-transplant 
Hb levels 
 
10.8±0.3 g/dl 
 
11.6±0.5 g/dl 
 
10.3±0.2 g/dl 
 
6 month post-
transplant Hb 
levels 
12.8±1.3 g/dl   13.4±1.4 g/dl   12.3±1.2 g/dl   
 
1 year post-
transplant Hb 
levels 
12.6±1.4 g/dl 13.2±1.5 g/dl   12.1±1.3 g/dl   
 
P value 
6 m post-tx vs 
pre-tx Hb levels 
0.0001   
P value 
6 month post-tx 
vs 1 yr post-tx 
Hb levels 
0.2566   
 
9.5
10
10.5
11
11.5
12
12.5
13
pre-tx 6m post.tx 1yr post.tx
 
 
Fig. 1. Hb (g/dl) levels in the pre-transplant, 6-month and 1-year period after renal transplantation. 
 
Prevalence of anemia defined by WHO (Hb <12 g/dl in 
females
 
and <13 g/dl in males) was 28.8%% at 6 months 
(34 out of 118) and 31.4%% at 1 year (37 out of 118).
 
 
The prevalence of ‗significant‘ anemia (Hb <11 g/dl in 
female and <12 g/dl in male) was still high: 15.3%
 
at 6 
months (14 out of 118) and 16.8% at 1 year (20 out of 
118). 
‗Severe‘ anemia (Hb <10 g/dl in both genders) at 6 
months post-transplant was less common affecting four
 
out of 118(3.4%) patients. Among these, all were 
females, and all were on AZA. At 1 year, 8
 
out of 118 
(6.8 %) had ‗severe‘ anemia. Of these, six were females 
and using
 
AZA and sirolimus (75%). 
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Table 3. Prevalence of anemia in our patients. 
 
  
At 6 months 
post-tx 
 
 
At 1 year 
post-tx 
 
Anemia as defined by WHO (Hb 
<12 g/dl in females and <13 g/dl in 
males)  
 
28.8% 
 
31.4% 
Significant anemia (Hb <11 g/dl in 
female and <12 g/dl in male) 
15.3% 16.8% 
Severe anemia (Hb <10 g/dl in both 
genders) 
 
3.4% 6.8 % 
 
Risk factors for anemia (tables 4,5): 
To elucidate the risk factors for anemia after 
transplantation,
 
we conducted the univariate analysis of 
possible risk factors
 for ‗significant‘ anemia defined as 
Hb level <11
 
g/dl in women and <12 g/dl in men. 
Univariate analysis showed
 
that a higher creatinine level 
and lower eGFR were significant
 
risk factors at 6 months 
and 1 year post transplant.
 
At 1 year, in addition to higher 
creatinine level and lower eGFR, female
 
gender and 
immunosuppressive drugs (AZA and sirolimus) also 
were a significant risk factors. 
 
Table 4. Factors associated with ‗significant‘ anemia by univariate analysis. 
 
 
Variables 
 
6 months post-tx 
 
  
1 year post-tx 
 
 Relative risk (95% CI) 
 
P value Relative risk (95% CI) P value 
 
eGFR 
 
3.86(2.34, 4.96) 
 
0.04 a 
 
4.46(2.7, 6.50) 
 
0.02 a 
Higher serum creatinine 1.98 (1.1, 3.82) 0.03a 2.24 (1.4, 3.2) 0.04 a 
Female gender 1.7 (1.3, 2.6) 0.135 2.8 (1.9, 4.6) 0.01a 
Lower pre-Tx Hb 1.4 (1.1, 1.7) 0.262 1.6 (1.3, 1.93) 0.073 
Episode of acute rejection 1.02 (0.53, 2.23) 0.534 0.92 (0.46, 1.58) 0.686 
Episode of DGF 0.98 (0.33, 2.1) 0.732 0.33 (0.09, 1.32) 0.152 
SLE as a cause of ESRD 1.1 (0.33, 3.26) 0.628 1.4 (0.47, 3.68) 0.214 
Use of AZA 0.57 (0.16, 1.45) 0.563 0.30 (0.21, 1.20) 0.05 a 
Use of MMF 0.9(0.28, 2.36) 0.611 0.27 (0.12, 1.28) 0.246 
Use of cyclosporine 1.12(0.48, 2.54) 0.521 0.37 (0.32, 1.48) 0.335 
Use of sirolimus 1.07 (0.66, 1.95) 0.472 0.70 (0.61, 1.50) 0.05 a 
Use of ACEI/ARBs 
 
1.36 (0.86, 2.71) 0.574 1.64 (0.97, 2.93) 0.329 
 
 
Pre-Tx, pre-transplant; DGF, delayed graft function.  
 
Table 5. Factors associated with ‗significant‘ anemia by multivariate analysis. 
  
 
Variables                                                                                                               Relative risk (95% CI)                      P value 
 
 
Risk of ‘significant’ anemia at 6 month post-transplant: 
    Higher serum creatinine                                                                                       1.98 (1.1, 3.82)                                 0.03 
    eGFR                                                                                                                    3.86(2.34, 4.96                                 0.04                                      
Risk of ‘significant’ anaemia at 1 year post-transplant: 
    Higher serum creatinine                                                                                       2.10 (1.01, 4.12)                               0.01 
    eGFR                                                                                                                     4.46(2.7, 6.50)                                  0.02 
    Female gender                                                                                                      2.87 (1.12, 6.21)                               0.01 
    Use of AZA                                                                                                          0.30 (0.21, 1.20)                               0.05 
    Use of sirolimus                                                                                                   0.70 (0.61, 1.50)                               0.05 
  
  
Multivariate analysis showed that at 6 months, higher 
creatinine levels and lower eGFR were significant 
independent risk
 
factors for anemia (p value = 0.03; p 
value=0.04 respectively)
 
and at 1 year, significant 
independent risk factors for anemia
 
included a higher 
creatinine level (P = 0.01), lower eGFR(p value=0.02), 
AZA and sirolimus(p value =0.05), and  female gender
 
(P 
= 0.01) even with a lower cut-off level of Hb by 1 g/dl
 
in 
defining anemia  compared with male gender.
 
 
 
Discussion 
 
Over the last years, the renal transplant community has 
shown a growing interest in the incomplete correction of 
anemia by the transplanted kidney. Between 25% and 
30% of these patients will be anemic at some time after 
transplantation. In addition to impaired kidney function, 
other factors may also play a role in the pathogenesis of 
post-transplant anemia: Immunosuppressive agents such 
as azathioprine, mycophenolate mofetil, and sirolimus; 
angiotensin-converting enzyme inhibitors and 
angiotensin-II receptor antagonists; impaired iron 
homeostasis; and donor and recipient age [11].  
After successful transplantation, erythropoiesis begins 
and
 
serum EPO level increases to a sustained level in a 
month and
 
subsequently Hb level increases towards 
normal within 3 months
 
[12]. This means that the Hb 
level should be completely normalized
 
by 6 months for 
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most patients as long as they have a good allograft
 
function. However, in some renal allograft recipients, 
anemia
 
persists or develops following transplantation. 
Most of them
 
are associated with preoperative blood loss, 
allograft dysfunction
 
(delayed graft function, acute 
rejection, chronic allograft
 
dysfunction) [13] although 
some have anemia with normal allograft
 
function as well 
[14].
 
 
In our study, we have shown that anemia is common 
(28.8% at 6 month and 31.4% at 1 yea post-transplant by
 
WHO criteria) and (15.6% at 6 month and 16.8% at 1 
year by definition with Hb <11 g/dl in females
 
and <12 
g/dl in males, although ‗severe‘ anemia (defined as Hb 
<10 g/dl) was not so common (3.4% at 6 month and 
6.8%
 
at 1 year).
 
 
The high prevalence of anemia in renal transplant 
recipients
 
has been reported elsewhere. Yorgin et al. 
observed adult renal
 
transplant recipients over a 5-year 
period and found 30% of
 
the patients experienced anemia 
(Ht<33%) during study period
 
[15]. In the study by 
Lorenz et al., prevalence of anemia (Hb<12
 
g/dl in 
females and <13 g/dl in males) was 39.7% [16]. Mix
 
et 
al., observed a high prevalence of anemia (Ht <36%) at
 
1 
year (21%) and at 4 years (36%) and found that treatment 
of
 
anemia with iron or EPO was not common even 
among those with
 
severe anemia [17]. An even large 
study from Europe
 
confirmed this high prevalence of 
anemia (38.6% during a 5-year
 
post-transplant enrolment 
period). Al-Khoury et al. identified anemia in 45.3% of 
adults and 22%
 
in children post-transplant [18]. All the 
studies including ours confirmed the high
 
prevalence of 
mild anemia after renal transplantation.
 
 
Among the possible risk factors, our study found that
 
a 
higher creatinine value, lower eGFR, female gender, 
AZA and sirolimus were the
 
only significant independent 
risk factors for posttransplant anemia.
 
 
Similar to our observations, other studies [19,20,7] have 
shown
 
that poor renal allograft function is an independent 
risk factor
 
for anemia. It is well described that production 
of EPO depends
 
on allograft function [18].
 
 
Also, more females than males had mild anemia both at 6 
months
 
and 1 year even though we set a lower threshold 
for Hb level
 
in females as a definition of anemia. The 
findings are consistent
 
with other studies showed
 
higher 
prevalence of anemia in females [9,18] and are 
inconsistent
 
in other studies. The large European study 
did not show any
 
gender difference in prevalence of 
anemia (defined as Hb ≤13 g/dl in males and ≤12 g/dl in 
females) [7]. Other studies showed
 
higher prevalence of 
anaemia in males [15,16]. The negative effect
 
of female 
gender on Hb level has been reported in dialysis [21]
 
and 
CKD patients [22].
 
 
The European study showed use of ACEI, ARB or AZA, 
MMF was associated
 
with higher prevalence of anemia 
[7]. Our study did not find
 
the association of use of ACEI 
or ARB with anemia, but there was association of use of 
AZA and sirolimus with anemia.
 
 
In our study iron profile was checked in 34 patients who 
had
 
anemia by WHO definition during the first  post-
transplant year
 
and 14 out of those 34 anemic  patients 
had ferritin levels <100
 
mg/dl or transferrin saturation 
<20%. All patients of these iron deficient patients had 
iron supplementation.
 
Only  six out of 34 patients were 
treated with EPO and all
 
of these patients had Hb <11 
g/dl.  Mix et
 
al., showed that among transplant recipients 
who had Ht
 
<30%, only 36% had iron studies, with 46% 
being supplemented
 
with iron and only 40% receiving 
EPO [17]. Vanrenterghem et al.
 
showed only 17.8% of 
severely anemic patients received EPO [7,10,11]. EPO 
levels tend to be
 
low in anemic renal transplant recipients 
irrespective of the
 
allograft function [23,24] and several 
studies have shown the
 
acceptable efficacy of EPO 
treatment in post-transplant anemia
 
[17,24]. So early 
investigation of anemia and iron deficiency
 
and its 
therapy with iron supplement or EPO should be 
considered
 
in anaemic transplant recipients.
 
 
In conclusion, we found that anemia is common during 
the first
 
year after transplantation and investigation and 
treatment of
 
anemia is suboptimal. We think that the
 
anemia check-up should be part of the long-term follow-
up of the renal transplant patients. Controlled trials 
should investigate the impact of a better control of 
anemia on the patient morbidity and outcome.  
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